Statins Safety Signals: From Precautions to Proportionate Evidence‐Based Labeling
Clinical Pharmacology & Therapeutics · 2026-10 · 120 (4) · 852-854
DOI: 10.1002/cpt.70419 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 28.07.2026. Verfasst von Médéa Locquet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences (NARILIS), Faculty …. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug Labeling, Evidence-Based Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The recent Cholesterol Treatment Trialists' Collaboration meta‐analysis provides the most comprehensive randomized evidence to date regarding statin‐associated adverse drug reactions, substantially narrowing the list of harms confidently attributable to statins. Beyond its clinical implications, the analysis highlights important challenges in pharmacovigilance and regulatory risk communication. Precautionary labeling based on low‐certainty evidence may inadvertently amplify nocebo effects, reduce adherence to preventive therapies, and contribute to avoidable cardiovascular burden, particularly among vulnerable populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium.
- Department of Pharmacy, Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium.
- Department of Cardiology, University of Liège Hospital, GIGA Institutes, Cardiovascular Sciences and Metabolism, CHU Sart Tilman, Liège, Belgium.
ORCID-Profile: Médéa Locquet, Jonathan Douxfils, Patrizio Lancellotti, Jean-Michel Dogné
Zitieren
APA
Locquet, M., Douxfils, J., Lancellotti, P., & Dogné, J. M. (2026). Statins Safety Signals: From Precautions to Proportionate Evidence‐Based Labeling. Clinical Pharmacology & Therapeutics, 120(4), 852-854. https://doi.org/10.1002/cpt.70419
Vancouver
Locquet M, Douxfils J, Lancellotti P, Dogné JM. Statins Safety Signals: From Precautions to Proportionate Evidence‐Based Labeling. Clinical Pharmacology & Therapeutics. 2026;120(4):852-854. doi:10.1002/cpt.70419
BibTeX
@article{Locquet2026,
author = {Locquet, Médéa and Douxfils, Jonathan and Lancellotti, Patrizio and Dogné, Jean-Michel},
title = {Statins Safety Signals: From Precautions to Proportionate Evidence‐Based Labeling},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {4},
pages = {852--854},
doi = {10.1002/cpt.70419}
}
EUVIMED